LORAZEPAM INJECTION USP SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

LORAZEPAM

Beszerezhető a:

PFIZER CANADA ULC

ATC-kód:

N05BA06

INN (nemzetközi neve):

LORAZEPAM

Adagolás:

4MG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

LORAZEPAM 4MG

Az alkalmazás módja:

INTRAMUSCULAR

db csomag:

1ML

Recept típusa:

Targeted (CDSA IV)

Terápiás terület:

BENZODIAZEPINES

Termék összefoglaló:

Active ingredient group (AIG) number: 0110731004; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2017-09-07

Termékjellemzők

_Product Monograph - Lorazepam Injection USP_
_Page 1 of 30 _
PRODUCT MONOGRAPH
LORAZEPAM INJECTION USP
(lorazepam)
Sterile Solution
4 mg/mL
Anxiolytic – Sedative
Pfizer Canada ULC
17300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5
Submission Control No.: 230606
Date of Revision:
August 22, 2019
_ _
_Product Monograph - Lorazepam Injection USP_
_Page 2 of 30 _
TABLE OF CONTENTS
ACTION
..............................................................................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................4
WARNINGS
........................................................................................................................4
PRECAUTIONS
..................................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
ADVERSE REACTIONS
..................................................................................................10
OVERDOSAGE
................................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
STORAGE AND STABILITY
..........................................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................16
DETAILED PHARMACOLOGY
.....................................................................................17
TOXICOLOGY
.................................................................................................................19
REFERENCES
...............